Investors question Nestlé CHC move
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Swiss food and drinks giant Nestlé should “better explain to shareholders the rationale behind expanding further into consumer healthcare”,says major shareholder Third Point.
You may also be interested in...
Hershey's Latest Sweet Spot In Nutritional Space: $397m For One Brands
Marketer long known for iconic Hershey's Kisses and other candy products looks to grow its nutritional market revenues with One Brands' products, complementing its Oatmega business and following its investment earlier in August in UK/Ireland maker of protein bars.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.